Form 8-K - Current report:
SEC Accession No. 0001213900-25-023762
Filing Date
2025-03-13
Accepted
2025-03-13 17:17:30
Documents
16
Period of Report
2025-03-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea023436601-8k_cadrenal.htm   iXBRL 8-K 26671
2 PRESS RELEASE ea023436601ex99-1_cadrenal.htm EX-99.1 80789
3 GRAPHIC ex99-1_001.jpg GRAPHIC 5731
4 GRAPHIC ex99-1_002.jpg GRAPHIC 6104
  Complete submission text file 0001213900-25-023762.txt   311310

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE cvkd-20250313.xsd EX-101.SCH 3060
6 XBRL LABEL FILE cvkd-20250313_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE cvkd-20250313_pre.xml EX-101.PRE 22389
18 EXTRACTED XBRL INSTANCE DOCUMENT ea023436601-8k_cadrenal_htm.xml XML 3801
Mailing Address 822 A1A NORTH SUITE 306 PONTE VEDRA FL 32082
Business Address 822 A1A NORTH SUITE 306 PONTE VEDRA FL 32082 904-300-0701
Cadrenal Therapeutics, Inc. (Filer) CIK: 0001937993 (see all company filings)

EIN.: 880860746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41596 | Film No.: 25736874
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)